800
Participants
Start Date
January 3, 2019
Primary Completion Date
July 30, 2027
Study Completion Date
July 30, 2027
Early Highly Effective Therapies Group
Highly Effective MS Therapy group of medications
Escalation Therapies Group
Escalation MS Therapy group of medications
University of Buffalo, Buffalo
University Rochester Medical Center, Rochester
University of Virginia, Charlottesville
Virginia Commonwealth University, Richmond
Ohio Health, Columbus
Cleveland Clinic, Cleveland
University of Cincinnati, Cincinnati
University of Wisconsin-Madison, Madison
University of Minnesota, Minneapolis
Mayo Clinic, Rochester
Baylor College of Medicine, Houston, Houston
UTHealth-Houston, Houston
UT-Austin, Austin
University of Colorado-Anschutz Medical Campus, Aurora
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas
University Hospitals Coventry and Warwickshire, Coventry
The Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Leeds
University Hospitals Leicester, Leicester
Imperial College Healthcare NHS Trust, Charing Cross Hospital, London
University College London Hospitals NHS Foundation Trust, University College Hospital, London
Salford Royal NHS Foundation Trust, Salford Hospital, Manchester
Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford
University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth
Sheffield Teaching Hospitals, Sheffield
University Hospitals of North Midlands, Stoke
Royal Infirmary of Edinburgh, Edinburgh
Cardiff and Vale University Local Health Board, University Hospital of Wales, Cardiff
Aneurin Bevan Local Health Board Headquarters, Royal Gwent Hospital, Newport
Swansea Bay University Local Health Board, Morriston Hospital, Swansea
Nottingham University Hospitals NHS Trust, Queens Medical Centre, Nottingham
University of Nottingham
OTHER
The Cleveland Clinic
OTHER